Oncology Institute, Inc. (TOI) Cost of Revenue (2021 - 2026)

Oncology Institute (TOI) has 5 years of Cost of Revenue data on file, last reported at $119.5 million in Q4 2025.

• Quarterly Cost of Revenue rose 161.29% year-over-year to $119.5 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $170.7 million (up 28.19% YoY) and the FY2025 annual result came in at $220.6 million, up 18.02% from the prior year.
• Cost of Revenue rose to $119.5 million in Q4 2025, from $51.2 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $120.7 million in Q4 2023 to a low of $113000.0 in Q3 2022.
• A 5-year average of $38.5 million and a median of $38.4 million in 2022 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2022 — Cost of Revenue plunged 99.55% — and 2023, when it soared 39688.5%.
• Tracing TOI's Cost of Revenue over 5 years: stood at $61.6 million in 2021, then tumbled by 37.7% to $38.4 million in 2022, then surged by 214.44% to $120.7 million in 2023, then sank by 62.1% to $45.7 million in 2024, then jumped by 161.29% to $119.5 million in 2025.
• The last three Cost of Revenue figures came in at $119.5 million (Q4 2025), $51.2 million (Q2 2025), and $47.1 million (Q1 2025), per Business Quant data.